Metsandia (Mometasone Furoate Monohydrate)

Metsandia, a nasal corticosteroid, is used to manage inflammation associated with allergic rhinitis.

• Allergic rhinitis: alleviates nasal congestion, sneezing, itching and rhinorrhea, improving overall nasal comfort.
• Seasonal allergic rhinitis: reduces symptoms triggered by pollen or other seasonal allergens, helping maintain daily activities during peak seasons.
• Perennial allergic rhinitis: controls year‑round nasal inflammation caused by indoor allergens, providing consistent symptom relief.

• Mometasone furoate monohydrate binds to intracellular glucocorticoid receptors in nasal mucosal cells, forming a complex that translocates to the nucleus and modulates gene transcription. This action suppresses the production of pro‑inflammatory cytokines, chemokines and adhesion molecules, leading to decreased vascular permeability, edema and inflammatory cell infiltration in the nasal passages, and thereby reduces the symptoms of allergic rhinitis through localized anti‑inflammatory activity without significant systemic exposure.

Metsandia may cause local and systemic adverse reactions, most of which are mild and reversible.

Common Side Effects

• Nasal irritation or burning sensation
• Headache
• Epistaxis (nosebleed)
• Throat irritation or dryness
• Altered sense of taste
• Cough

Serious or Rare Side Effects

• Nasal septal perforation
• Severe or persistent epistaxis
• Adrenal suppression with prolonged use
• Cataract formation or increased intra‑ocular pressure
• Fungal infection of the nasal mucosa
• Anaphylactic reaction

Before using Metsandia, consider the following precautions to ensure safe and effective therapy.

• Pediatric use: follow prescriber guidance and monitor for growth effects.
• Prolonged use: limit duration to the shortest effective period to avoid systemic effects.
• Nasal surgery or trauma: avoid use until healing is complete.
• Glaucoma or cataract history: use with caution and monitor intra‑ocular pressure.
• Immunocompromised patients: watch for opportunistic infections.
• Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Metsandia can interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid)

• Systemic corticosteroids: increased risk of adrenal suppression.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise local drug exposure.
• Ritonavir or other protease inhibitors: potential for enhanced glucocorticoid effects.
• Antifungal agents such as fluconazole: may increase systemic absorption.
• Live vaccines: reduced efficacy due to immunosuppression.

Moderate Interactions (Monitor Closely)

• Nasal decongestants (e.g., oxymetazoline): may increase local irritation.
• Antihistamines: monitor for additive sedation if first‑generation agents are used.
• Other intranasal medications: assess for cumulative local effects.
• Herbal supplements containing St. John’s wort: possible CYP3A4 induction reducing efficacy.